Biopharmaceutical Market serves as a Catalyst for Healthcare Innovation

The global Biopharmaceuticals market size is expected to be valued at USD 250.50 billion in 2024 and reach USD 389.15 billion by 2029, growing at a CAGR of 9.2% from 2024 to 2029.
Biopharmaceuticals are complex medicines made from living cells or organisms produced using biotechnological methods. They are considered advanced treatment options for patients.

Global Biopharmaceuticals Market Report Scope:
• Market Size (2029): USD 250.50 Billion
• Market Size (2023): USD 389.15 Billion
• CAGR (2024 to 2029): 9.2%
• Base Year: 2023
• Forecast Period: 2024 to 2029
• Segments Analysed: Product Type, Therapeutic Type, and Region
• Geographies Covered: North America, Europe, APAC, Latin America, and Middle East & Africa
• Key Market Players Profiled: Merck & Co., Inc., F. Hoffmann- La Roche AG, Eli Lilly and Company, Inc., Sanofi, Amgen Inc., AbbVie Inc., Biogen Idec, Bayer AG, Johnson & Johnson Services, Pfizer, Inc. and Novartis AG. Are playing a dominant role in the global In
Biopharmaceuticals market.

The growing geriatric population with the prevalence of chronic diseases and augmenting infectious diseases worldwide is prominently contributing to the adoption of biopharmaceuticals in the healthcare industry, enhancing market growth. The demand for biopharmaceuticals is escalating in chronic and genetic disorders like cancer, autoimmune disorders, diabetes, and cardiovascular diseases due to advanced treatment options driving the market expansion globally. Biopharmaceuticals are expected to treat untreatable diseases, driving the market growth. According to a WHO report, in September 2022, about 55 million people around the world are living with dementia, and nearly 10 million cases are reported annually. The growing investments in R&D by the market players and the government to develop innovative drugs for therapeutic action are enhancing the demand for biopharmaceuticals, which drives the global market revenue. For Instance, in September 2022, the Center for Biologics Evaluation and Research approved Bluebird Bio, Inc. product SKYSONA, which is indicated to slow the progression of neurologic dysfunction in boys aged 4 to 17 years with cerebral adrenoleukodystrophy. These innovations in the therapeutics are estimated to boost the market growth.
The increasing number of product approvals and launches due to the active role of the EMA and FDA in monitoring and providing approvals in the biopharmaceutical industry is escalating the market revenue. The growing presence of contract research organizations and manufacturing organizations across the globe is making a significant contribution to the expansion of the biopharmaceutical market. The escalating government initiatives, collaborations in the biopharmaceutical companies, and funding are enhancing the market growth.

The high costs associated with the R&D activities for drug development and their threat of failure are expected to restrain the market growth. The market players in research require high investments to develop innovative drug moieties, limiting biopharmaceuticals' growth. The presence of specific adverse reactions with the administration of biopharmaceutical drugs, such as allergic reactions, increased risk of infection, and chemical interactions, will hamper the growth of market revenue. The presence of complicated regulatory requirements and standards in the manufacturing of high-end products is estimated to hinder the market expansion of biopharmaceuticals during the forecast period. The approval rate of new drugs is prolonged, and various stringent government regulations lead to delays in production and product launches by impeding market growth.


Browse full details of the report @ https://www.marketdataforecast.com/market-reports/bio-pharmaceuticals-market

Key Insights from The Report:

• By product type, the monoclonal antibodies segment led the market and accounted for the largest share of the global market in 2023.
• Based on therapeutic type, the oncology segment captured highest share of the global market in 2023.
• Based on therapeutic type, the diabetes and CVDs segments are anticipated to showcase a healthy CAGR in the coming years.
• North America dominated the Biopharmaceuticals market in 2023. Europe accounted for second-highest share of the global market in 2023 and on the other hand, the Asia-Pacific region is estimated to grow at the fastest CAGR during the forecast period.
• CooperSurgical, Inc. (U.S.), Vitrolife AB (Sweden), Cook Medical, Inc. (U.S.), Irvine Scientific (U.S.), Thermo Fisher Scientific, Inc. (U.S.), EMD Serono, Inc. (U.S.), Genea Limited (Australia), ESCO Micro Pte. Limited (Singapore), IVFtech ApS (Denmark), are dominated the Biopharmaceuticals market.

SEGMENTATION INCLUDED IN THIS REPORT:

By Product Type:
• Embryo Culture Media
• Cryopreservation Media
• Sperm Processing Media
• Ovum Processing Media
By Therapeutic type:
• Imaging Systems
• Sperm Separation Systems
• Ovum Aspiration Pumps
• Incubators
• Micromanipulator Systems
• Cryptosystems
• Other Instruments (Gas Analyzers, Laser Systems, Accessories)
By Region:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Browse Regional Reports:

North America Biopharmaceuticals Market Research Report - Segmented By Product Type, Therapeutic Type & Country (U.S, Canada & Rest of North America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2024 to 2029) - https://www.marketdataforecast.com/market-reports/north-america-bio-pharmaceuticals-market
Europe Biopharmaceuticals Market Research Report - Segmented By Product Type, Therapeutic Type & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2024 to 2029) - https://www.marketdataforecast.com/market-reports/europe-bio-pharmaceuticals-market
APAC Biopharmaceuticals Market Research Report - Segmented By Product Type, Therapeutic Type & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2024 to 2029) - https://www.marketdataforecast.com/market-reports/asia-pacific-bio-pharmaceuticals-market
Latin America Biopharmaceuticals Market Research Report - Segmented By Product Type, Therapeutic Type & Country (Brazil, Argentina, Chile and Rest of Latin America) - Industry Analysis, Size, Share, Growth, Trends, & Forecast (2024 to 2029) - https://www.marketdataforecast.com/market-reports/latin-america-bio-pharmaceuticals-market
Middle East & Africa Biopharmaceuticals Market Research Report - Segmented By Product Type, Therapeutic Type & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan and Rest of MEA) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast from 2024 to 2029 - https://www.marketdataforecast.com/market-reports/middle-east-and-africa-bio-pharmaceuticals-market

TABLE OF CONTENTS:

1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Product Type
5.1.1 Monoclonal Antibodies (mAb)
5.1.2 Erythropoietin
5.1.3 Biotech Vaccines
5.1.4 Recombinant Human (RH) Insulin
5.1.5 Granulocyte colony-stimulating factor (G-CSF)
5.1.6 Interferon
5.1.7 Human growth hormones (HGH)
5.2 By Therapeutic Type
5.2.1 Neurology
5.2.2 Infectious diseases
5.2.3 Diabetes
5.2.4 Oncology
5.2.5 Cardiovascular
5.2.6 Other Therapeutic Areas
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Mexico
6.4.4 Argentina
6.4.5 Rest of Latin America
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter's Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Merck & Co.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 F. Hoffmann-La Roche AG
8.3 Eli Lilly and Company
8.4 Sanofi
8.5 Amgen Inc.
8.6 AbbVie Inc.
8.7 Biogen Idec
8.8 Bayer AG
8.9 Johnson & Johnson Services
8.10 Pfizer
8.11 Novartis AG
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures

Contact Us:
Market Data Forecast
www.marketdataforecast.com
Phone: +1-888-702-9626
Email: sales@marketdataforecast.com
5th Floor, Trendz Pride, Patrika Nagar Rd Number 1, HUDA Techno Enclave, HITEC City, Hyderabad, Telangana 500081, India

About Us:
Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients.

This release was published on openPR.